On Tuesday, Vivani Medical Inc (NASDAQ:VANI) announced the publication of positive proof-of-concept weight loss data with OKV-119 to treat feline obesity and diabetes in the peer-reviewed BMC ...

While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...

Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ:VANI) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company’s weight-loss solution, ...

Wirelessly rechargeable brain implants could make it easier for researchers to control individual neurons in rats using pulses of lights. Optogenetics is a research tool in neuroscience that uses ...

In modern times, a portable storage device isn't far from our possession. Either we can use the storage on our phones or tablets, or we keep a small flash drive on a keychain. Accessing the data, ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...